Rezultati - Ignacio Garrido‐Laguna
- Showing 1 - 20 results of 37
- Go to Next Page
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center od Ignacio Garrido‐Laguna, Filip Janků, Christos Vaklavas, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, Apostolia M. Tsimberidou, Sijin Wen, Razelle Kurzrock
Izdano 2011Artigo -
9
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers od Filip Janků, J. Jack Lee, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Siqing Fu, Rajyalakshmi Luthra, Ignacio Garrido‐Laguna, Razelle Kurzrock
Izdano 2011Artigo -
10
KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors od Ignacio Garrido‐Laguna, David S. Hong, Filip Janků, Ly M. Nguyen, Gerald S. Falchook, Siqing Fu, J. J. Wheler, Rajyalakshmi Luthra, Aung Naing, Xuemei Wang, Razelle Kurzrock
Izdano 2012Artigo -
11
A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer od Manuel Hidalgo, Elizabeth Bruckheimer, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Elizabeth De Oliveira, Belén Rubio‐Viqueira, Steven J. Strawn, Michael J. Wick, James Martell, David Sidransky
Izdano 2011Artigo -
12
A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors od Niharika B. Mettu, Susanna V. Ulahannan, Johanna C. Bendell, Ignacio Garrido‐Laguna, John H. Strickler, Kathleen N. Moore, Robert Stagg, Ann M. Kapoun, Leonardo Faoro, Sunil Sharma
Izdano 2021Artigo -
13
<i>PIK3CA</i> Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors od Filip Janků, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock
Izdano 2011Artigo -
14
PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring <i>PIK3CA</i> Mutations od Filip Janků, Jennifer J. Wheler, Shannon N. Westin, Stacy Moulder, Aung Naing, Apostolia M. Tsimberidou, Siqing Fu, Gerald S. Falchook, David S. Hong, Ignacio Garrido‐Laguna, Rajyalakshmi Luthra, J. Jack Lee, Karen H. Lu, Razelle Kurzrock
Izdano 2012Artigo -
15
Personalizing Cancer Treatment in the Age of Global Genomic Analyses: <i>PALB2</i> Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer od Maria Cristina Villarroel, N.V. Rajeshkumar, Ignacio Garrido‐Laguna, Ana De Jesus‐Acosta, Siân Jones, Anirban Maitra, Ralph H. Hruban, James R. Eshleman, Alison P. Klein, Daniel A. Laheru, Ross C. Donehower, Manuel Hidalgo
Izdano 2010Artigo -
16
PIK3CA Mutations in Advanced Cancers: Characteristics and Outcomes od Filip Janků, Jennifer J. Wheler, Aung Naing, Vanda M. Stepanek, Gerald S. Falchook, Siqing Fu, Ignacio Garrido‐Laguna, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Stacy Moulder, J. Jack Lee, Rajyalakshmi Luthra, David S. Hong, Razelle Kurzrock
Izdano 2012Artigo -
17
First‐in‐human, phase I study of PF‐06647263, an anti‐EFNA4 calicheamicin antibody–drug conjugate, in patients with advanced solid tumors od Ignacio Garrido‐Laguna, Ian E. Krop, Howard A. Burris, Erika Hamilton, Fadi Braiteh, Amy Weise, Maysa Abu‐Khalaf, Theresa L. Werner, Steven Pirie‐Shepherd, Christopher J. Zopf, Mani Lakshminarayanan, Jaymes Holland, Raffaele Baffa, David S. Hong
Izdano 2019Artigo -
18
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors od Anthony B. El-Khoueiry, James S. Clarke, Tobias Neff, T. Crossman, Nirav Ratia, Chetan Rathi, Paul Noto, Aarti Tarkar, Ignacio Garrido‐Laguna, Emiliano Calvo, Jordi Rodón, Ben Tran, Peter J. O’Dwyer, Adam Cuker, Albiruni R. Abdul Razak
Izdano 2023Artigo -
19
Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC od Vaia Florou, Andrew Elliott, Matthew H. Bailey, David Stone, Kajsa E. Affolter, Heloisa P. Soares, Christopher Nevala-Plagemann, Courtney L. Scaife, Phillip Walker, W. Michael Korn, Emil Lou, Rachna T. Shroff, Peter J. Hosein, Ignacio Garrido‐Laguna
Izdano 2023Artigo -
20
652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (... od Kathryn C. Arbour, Salman Rafi Punekar, Ignacio Garrido‐Laguna, David S. Hong, Brian M. Wolpin, Meredith S. Pelster, M. Barve, Alexander Starodub, D. Sommerhalder, Sam S. Chang, Y. Zhang, Zeena Salman, X. Wang, Corinne E. Gustafson, Alexander I. Spira
Izdano 2023Artigo
Iskalna orodja:
Sorodne teme
Medicine
Internal medicine
Cancer
Oncology
Colorectal cancer
Cancer research
Pancreatic cancer
Biology
Gene
KRAS
Disease
Genetics
Biochemistry
Gastroenterology
Gemcitabine
General surgery
Immunology
Mutation
Pharmacology
Adenocarcinoma
Breast cancer
Clinical trial
Immunotherapy
PI3K/AKT/mTOR pathway
Pathology
Radiation therapy
Signal transduction
Adverse effect
Antibody
Chemistry